Immunosuppressants

Immunosuppression in Bone Marrow Transplant
Ashley Newland, PharmD
BMT_2011.ppt

Immunosuppression for Cardiac Transplantation
Immunosuppression.ppt

Transplant Associated Thrombotic Microangiopathy (TA-TMA)
Kristen Sanfilippo MD
Transplant Associated Thrombotic Microangiopathy.ppt

Agents Which Affect the Immune Response
Dan Fernandez
Agents Which Affect the Immune Response.ppt

Immunosuppressants
Immunosuppressants.ppt

Care of the Post-OLT Patient
George Makar
CareofthePostOLTPatient.ppt

Dermatology
Pediatrics/Dermatology.ppt

Eczema Atopic Dermatitis
Eczema Atopic Dermatitis.ppt

Introduction to Transplantation  Immunosuppression
Transplantation  Immunosuppression.ppt

Organ Transplant and Recovery 
K. Brooks, RN, MSNEd
Organ Transplant and Recovery .ppt

Transplantation Immunology
Mitchell S. Cairo, MD
Transplantation Immunology.ppt

Hypersensitivity Disorders
Hypersensitivity Disorders.ppt

Thrombotic Microangiopathy after Stem Cell Transplant
Janakiraman Subramanian M.D.
Thrombotic Microangiopathy after Stem Cell Transplant.ppt

Chronic GVHD: in Search of a Model to Understand its Pathobiology
Mark A. Schroeder, M.D.
Chronic GVHD.ppt

Post PCI Contrast Induced Nephropathy
Brandon M. Williams M.D
Post PCI Contrast Induced Nephropathy.ppt

Calcium entry and calcium signaling – different routes, different roles
Calcium entry and calcium signaling.ppt

Atopic Dermatitis
Nnenna G. Agim, MD
Atopic Dermatitis.ppt

Drugs in the Therapy of Transplant Rejection
Dr. Thomas Abraham
ImmunosuppressiveAgents.ppt

Principles of Pharmacology Immunomodulators
Dr. Laure Aurelian
Principles of Pharmacology Immunomodulators.ppt

Care of Clients with Altered Immunity
Care of Clients with Altered Immunity.ppt
467 Published articles list

1. 32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency.
2. A case of tongue neoplasm in a 15-year old patient treated with immunosuppressants for renal insufficiency.
3. A case of Wegener's granulomatosis complicated with cytomegalovirus pneumonia during the treatment with immunosuppressants.
4. A conserved docking surface on calcineurin mediates interaction with substrates and immunosuppressants.
5. A new assay method for immunosuppressants with a tacrolimus (FK506)-like mode of action.
6. A new fluorochromasia assay for sensitivity of lymphocytes to immunosuppressants.
7. A new quantitative GVH assay: simultaneous estimation of mitostatic and lymphotoxic effects of immunosuppressants.
8. A rapid method for in vitro screening of immunosuppressants using mouse spleen cells.
9. A retrospective study on the utilization of and expenditure for immunosuppressants for organ transplant recipients in Taiwan--updated to 2006.
10. A strategy for organ allografts without using immunosuppressants or irradiation.
11. A study of combined treatment with chemical immunosuppressants and antilymphocytic serum to prolong skin allograft survival.
12. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics.
13. Acute spontaneous tumor lysis syndrome in a patient with Crohn's disease taking immunosuppressants.
14. Acutely exaggerated hepatitis B induced by the withdrawal of immunosuppressants in a seroconverted renal transplant recipient: report of a case.
15. Adherence to immunosuppressants: how can it be improved in adolescent organ transplant recipients?
16. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients.
17. Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overview.
18. Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism.
19. Agonist-specific modulation of glucocorticoid receptor-mediated transcription by immunosuppressants.
20. Allogeneic and Xenogeneic Transplantation of Adipose-Derived Stem Cells in Immunocompetent Recipients without Immunosuppressants.
21. Aminoacyl-tRNA synthetase inhibitors as potent and synergistic immunosuppressants.
22. An experimental system for the simultaneous estimation of mitostatic and lymphotoxic effects of immunosuppressants and cytostatics.
23. An implantable pump for intrarenal infusion of immunosuppressants in a canine autotransplant model.
24. An introduction to immunosuppressants.
25. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants.
26. Anesthetic implications of immunosuppressants used for transplantation.
27. Antilymphocyte serum and procarbazine compared as immunosuppressants in mice, rats and rabbits.
28. Antiserum to lymphocytes and procarbazine compared as immunosuppressants in mice.
29. Antiserum to lymphocytes: interactions with chemical immunosuppressants.
30. Apoptosis and caspase-3 in long-term renal ischemia/reperfusion injury in rats and divergent effects of immunosuppressants.
31. Application of immunosuppressants for therapy of patients with vasculitis.
32. Appropriate use of immunosuppressants after renal transplantation.
33. Association between effective dose of prednisolone, alone or in conjunction with other immunosuppressants, and titre of anti-bullous pemphigoid 180 antibody: a retrospective study of 42 cases.
34. Association of systemic steroids and mycophenolate mofetil as rescue therapy for uveitic choroidal neovascularization unresponsive to the traditional immunosuppressants: interventional case series.
35. Asthma refractory to glucocorticoids: the role of newer immunosuppressants.
36. Atopic dermatitis=immunosuppressants?.
37. Automated processing of whole blood samples for the determination of immunosuppressants by liquid chromatography tandem-mass spectrometry.
38. Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection.
39. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants.
40. Awareness of memory impairment increases the adherence to immunosuppressants in kidney transplant recipients.
41. Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center.
42. Azoospermia in patients with kidney diseases taking immunosuppressants long term.
43. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants.
44. Bioequivalence testing of immunosuppressants: concepts and misconceptions.
45. Biological immunosuppressants: the way to clinical transplantation tolerance.
46. Biological reagents for immunosuppressants.
47. Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood.
48. Biosynthesis of the immunosuppressants FK506, FK520, and rapamycin involves a previously undescribed family of enzymes acting on chorismate.
49. Bone marrow-derived mesenchymal stem cells as immunosuppressants in liver transplantation: a review of current data.
50. Bowen's disease of the eyelid in a renal transplant recipient on immunosuppressants.
51. C4d deposition is associated with chronic allograft nephropathy in rats and could be influenced by immunosuppressants.
52. Calcineurin and cyclophilin D are differential targets of neuroprotection by immunosuppressants CsA and FK506 in ischemic brain damage.
53. Cardiac magnetic resonance imaging in Churg-Strauss-syndrome. Impact of immunosuppressants on outcome assessed in a prospective study on 8 patients.
54. CDT transferrin level as an aspect in choice of immunosuppressants after kidney transplantation.
55. Cell mediated immunity in rheumatoid arthritis: Imparied lymphocyte responsiveness, humoral immunosuppressants, and correlations with clinical status in patients off drug therapy.
56. Change in regulations for dispensing immunosuppressants to patients who have undergone a kidney transplant.
57. Changes in cells in the terminal portions of the pancreas following resection and administration of immunosuppressants.
58. Changes of Treg-Associated Molecules on CD4(+)CD25 (+)Treg Cells in Myasthenia Gravis and Effects of Immunosuppressants.
59. Characterization of methyltransferase and hydroxylase genes involved in the biosynthesis of the immunosuppressants FK506 and FK520.
60. Characterization of the delayed hypersensitivity response to a protein antigen in the mouse--I. Kinetics of reactivity and sensitivity to classical immunosuppressants.
61. Choice of immunosuppressants and the risk of warts in renal transplant recipients.
62. Citrus grandis peel increases the bioavailability of cyclosporine and tacrolimus, two important immunosuppressants, in rats.
63. Classification for two isolates of Microbispora producing immunosuppressants.
64. Clinical impact of lymphocyte sensitivity to immunosuppressants.
65. Clinical observations on varicella-zoster vaccinees treated with immunosuppressants for a malignancy.
66. Clinical use of immunosuppressants in Duchenne muscular dystrophy.
67. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis.
68. CNS aspergillosis in a patient with Crohn's disease on immunosuppressants: a case report.
69. Combined treatment of immune nephropathies with plasmapheresis and immunosuppressants.
70. Combined treatment with antioxidants and immunosuppressants on cytokine release by human peripheral blood mononuclear cells - chemically injured keratocyte reaction.
71. Commentary on new xenobiotic immunosuppressants for transplantation: Where are we, how did we get here, and where are we going?
72. Comparative actions of immunosuppressants, glucocorticoids and non-steroidal anti-inflammatory drugs on various models of delayed hypersensitivity and on a non-immune inflammation in mice.
73. Comparative investigation of the effects of the immunosuppressants cyclosporine A, cyclosporine G, and FK-506 on platelet activation.
74. Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function.
75. Comparison of endotoxins and cutaneous burn toxin as immunosuppressants.
76. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD.
77. Comparison of the L-asparaginases from Escherichia coli and Erwinia carotovora as immunosuppressants.
78. Complications during the use of immunosuppressants (literature survey).
79. Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus.
80. Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus.
81. Connection between immunosuppressants and steroids via HSP90.
82. Construction of Saccharomyces cerevisiae strain FAV20 useful in detection of immunosuppressants produced by soil actinomycetes.
83. Controlling the generation and function of human CD8+ memory T cells in vitro with immunosuppressants.
84. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
85. Converting nonhuman primate dendritic cells into potent antigen-specific cellular immunosuppressants by genetic modification.
86. Coping with rejection: immunosuppressants and organ transplantation.
87. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels.
88. Corticosteroid-sparing agents: conventional systemic immunosuppressants.
89. Cryptococcus neoformans infection in ulcerative colitis with immunosuppressants.
90. Cyclolinopeptides and their analogs--a new family of peptide immunosuppressants affecting the calcineurin system.
91. Cyclosporine and tacrolimus: a comparison of immunosuppressants used for liver transplantation.
92. Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors.
93. Cytomegalovirus hepatitis in a nontransplant patient with autoimmune hepatitis taking immunosuppressants.
94. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants.
95. Demonstration of ternary immunophilin-calcineurin complexes with the immunosuppressants cyclosporin and macrolide FK506.
96. Desquamative interstitial pneumonitis causing acute respiratory failure, responsive only to immunosuppressants.
97. Determination of absolute configuration and biological activity of new immunosuppressants, mycestericins D, E, F and G.
98. Determination of anti-acetylcholine receptor antibodies in myasthenia and its treatment by plasma exchange and immunosuppressants.
99. Development of calcineurin blocking non-steroid topical immunosuppressants for effective management of eczema.
100. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation.
101. Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other P-glycoprotein ligands.
102. Differential dose adjustments of immunosuppressants after resuming boosted versus unboosted HIV-protease inhibitors postliver transplant.
103. Differential effects of immunosuppressants and antibiotics on human monoclonal antibody production in SCID mouse ascites by five heterohybridomas.
104. Differential effects of immunosuppressants on lymphocyte function.
105. Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression.
106. Differential transcriptional regulation of endothelin-1 by immunosuppressants FK506 and cyclosporin A.
107. Disappearance of minimal residual disease after the early withdrawal of immunosuppressants in a patient with juvenile myelomonocytic leukemia.
108. Discovery and development of immunosuppressants for transplantation: what are the lessons for specialty medicines?
109. Discovery of novel immunosuppressants in vitro
110. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
111. Distribution characteristics of immunosuppressants FK506 and cyclosporin A in the blood compartment.
112. Do immunosuppressants affect the survival of hepatitis C patients receiving kidney transplants?.
113. Do immunosuppressants cause posttransplant diabetes mellitus?
114. Do immunosuppressants directly affect neutrophils, resulting in protection of the liver against ischemia-reperfusion injury?
115. Do immunosuppressants really work as maintenance therapy after the achievement of remission of severe ulcerative colitis?
116. Donor leukocyte transfusions and discontinuation of immunosuppressants to achieve an initial remission after allogeneic bone marrow transplantation in a patient with primary refractory acute leukemia.
117. Down regulation of CD4 expression in cultured microglia by immunosuppressants and lipopolysaccharide.
118. Down-regulated NOD2 by immunosuppressants in peripheral blood cells in patients with SLE reduces the muramyl dipeptide-induced IL-10 production.
119. Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants.
120. Drug interactions: a contribution to the rational use of synthetic and biological immunosuppressants.
121. Dynamic studies of skin microcirculation during treatment of lupus nephritis with cytostatic immunosuppressants.
122. Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis.
123. Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis.
124. Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis.
125. EBM analysis: classic DMARDs (disease-modifying antirheumatic drugs) and immunosuppressants in arthritis and uveitis.
126. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants.
127. Effect of adjusting the immunosuppressants on the prognosis of the infection in the patients with liver transplantation.
128. Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus.
129. Effect of certain immunosuppressants on non-specific immunity cells in murine corneal grafts: study on early phases after transplantation.
130. Effect of immunosuppressants FK506 and rapamycin on the function of progesterone receptor: protein "p59-HBI", intersection between immunology and endocrinology?.
131. Effect of immunosuppressants in mice: Part I--Promethazine hydrochloride and hydrocortisone acetate treatments during experimental infections of Ancylostoma caninum and Nematospiroides dubius.
132. Effect of immunosuppressants on dogs exposed two and one-half years previously to Blastomyces dermatitidis.
133. Effect of immunosuppressants on lipids.
134. Effect of immunosuppressants on OKT3 associated T cell activation: clinical implications.
135. Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling.
136. Effect of immunosuppressants on the enhanced sensitivity of white mice to the eastern equine encephalitis virus.
137. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells.
138. Effect of immunosuppressants on the subrenal capsule (SRC) assay as a chemosensitivity test.
139. Effect of the immunosuppressants FK506 and D-allose on allogenic orthotopic liver transplantation in rats.
140. Effect of the immunosuppressants on hepatocyte cells proliferation and apoptosis during liver regeneration after hepatectomy - molecular studies.
141. Effect of the immunosuppressants on hepatocyte proliferation and apoptosis in a young animal model of liver regeneration: an immunohistochemical study using tissue microarrays.
142. Effects of commonly used immunosuppressants on graft-derived fibroblasts.
143. Effects of cytotoxic immunosuppressants on tuberculin-sensitive lymphocytes in guinea pigs.
144. Effects of immunosuppressants after penetrating keratoplasty: meta-analysis of randomized controlled trials.
145. Effects of immunosuppressants FK506 and rapamycin on the heterooligomeric form of the progesterone receptor.
146. Effects of immunosuppressants on concanavalin A-induced interleukin-2 mRNA expression in mouse liver.
147. Effects of immunosuppressants on cultured rat macrophages and Schwann's cells.
148. Effects of immunosuppressants on cytokine expressions after repair for nerve injury in a rat model.
149. Effects of immunosuppressants on hepatocyte cell mitosis during liver regeneration in growing animal models of partial hepatectomy.
150. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen.
151. Effects of immunosuppressants on platelet-derived growth factor-A chain mRNA expression and coronary arteriosclerosis in rat cardiac allografts.
152. Effects of immunosuppressants on proliferation of pheochromocytoma 12 and L929 cells.
153. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
154. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy.
155. Effects of immunosuppressants, calcineurin inhibition, and blockade of endoplasmic reticulum calcium channels on free fatty acid efflux from the ischemic/reperfused rat cerebral cortex.
156. Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis.
157. Effects of the immunosuppressants cyclosporin A and FK 506 on exocytosis in the rat exocrine pancreas in vitro.
158. Efficacy of combined therapy with plasmapheresis and immunosuppressants in rheumatoid vasculitis.
159. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.
160. Electroencephalographic (EEG) findings in posterior reversible encephalopathy associated with immunosuppressants.
161. Engrafting fetal liver cells into multiple tissues of healthy adult mice without the use of immunosuppressants.
162. Enhanced apoptosis in post-liver transplant hepatitis C: Effects of virus and immunosuppressants.
163. Enhancing and suppressive effects of immunosuppressants cyclosporin A, FK506, and KM2210 on the colony formation of murine bone marrow cells.
164. Enzymes as immunosuppressants: basic considerations.
165. Establishment of a cell model targeted to NFAT signal transduction pathway for preliminary screening of FK506-like immunosuppressants.
166. Evaluating the effects of immunosuppressants on human immunity using cytokine profiles of whole blood.
167. Evaluation of immunosuppressants and dietary mechanisms in an experimental disease model for necrotic enteritis.
168. Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy.
169. Evaluation of the ameliorative effects of immunosuppressants on crescentic glomerulonephritis in SCG/Kj mice.
170. Evaluation of the effects of immunosuppressants on neuronal and glial cells in vitro by multinuclear magnetic resonance spectroscopy.
171. Exacerbation of Whipple disease by immunosuppressants.
172. Excellent endpoints from step-down bridge combination therapy of 5 immunosuppressants in NSAID-refractory ankylosing spondylitis: 6 year international study in Asia - WHO-ILAR COPCORD stage II treatment of the autoimmune diseases.
173. Experience with cyclosporine and prednisone as immunosuppressants in 36 renal transplants.
174. Experiences of high-dose mizoribine as antimetabolite immunosuppressants for kidney transplantation.
175. Expression of beneficial blood transfusion effect in dogs is dependent upon immunosuppressants used.
176. Extensive skeletal muscle uptake of 18F-FDG: relation to immunosuppressants?
177. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.
178. Fas antigen expression of hepatocytes and its modification by immunosuppressants.
179. Fatal acute hepatitis B virus infection while receiving immunosuppressants after renal transplantation.
180. FDA approves new immunosuppressants.
181. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group.
182. Flow cytometric detection of intracellular IL-12 release: in vitro effect of widely used immunosuppressants.
183. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. I. Taxonomy of the producing strain.
184. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics.
185. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review.
186. Fumaric acid esters are potent immunosuppressants: inhibition of acute and chronic rejection in rat kidney transplantation models by methyl hydrogen fumarate.
187. Fungal metabolites. Part 14. Novel potent immunosuppressants, mycestericins, produced by Mycelia sterilia.
188. Generic immunosuppressants in hematopoietic cell transplantation.
189. Generic Immunosuppressants. Proceedings of a symposium. Montreal, Canada, July 12, 1998.
190. Generic immunosuppressants: the European perspective.
191. Genetic factors for individual administration of immunosuppressants in organ transplantation.
192. Gingival enlargement among renal transplant recipients in the era of new-generation immunosuppressants.
193. Glial migration inhibition test in multiple sclerosis patients and its changes during treatment with immunosuppressants.
194. Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles.
195. Good metabolic control using tacrolimus-based immunosuppressants in primary cadaveric renal transplantation in Chinese--a preliminary report.
196. Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants.
197. Hepatotoxicity induced by new immunosuppressants.
198. Hepatotoxicity of immunosuppressants. Diagnostic approach.
199. Higher approval standards, consistent practice policies needed for safe use of generic immunosuppressants, say transplant experts.
200. Humoral immunosuppressants of endogenous origin as an immunobiologic problem.
201. Hypoplastic myelodysplastic syndrome progressing to acute myelocytic leukemia (M2) after treatment with G-CSF and immunosuppressants.
202. IL-2 responsiveness of lectin-induced lymphoblasts: soluble IL-2 receptor release and differential in vitro effects of immunosuppressants.
203. IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A.
204. Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants.
205. Immunoblastic lymphadenopathy in a five-month-old girl: successful treatment with immunosuppressants.
206. Immunologic monitoring of monoclonal antibody therapy: comparison of five antibodies as immunosuppressants of renal allograft rejection.
207. Immunomodulators and immunosuppressants for Japanese patients with ulcerative colitis.
208. Immunophilin ligands: from immunosuppressants to neuroprotective drugs.
209. Immunosuppressants accelerate microvascular thrombus formation in vivo: role of endothelial cell activation.
210. Immunosuppressants and calcineurin inhibitors, cyclosporin A and FK506, reversibly inhibit epileptogenesis in amygdaloid kindled rat.
211. Immunosuppressants and Crohn's disease.
212. Immunosuppressants and multiple sclerosis.
213. Immunosuppressants and operation in ulcerative colitis.
214. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975.
215. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin.
216. Immunosuppressants and TGF-beta 1 accelerated and prolonged the nitric oxide/oxyradicals-dependent suppression by dexamethasone in paw edema of mice.
217. Immunosuppressants decrease neutrophil chemoattractant and attenuate ischemia/reperfusion injury of the liver in rats.
218. Immunosuppressants enhance superoxide radical/nitric oxide-dependent dexamethasone suppression of ischemic paw edema in mice.
219. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype.
220. Immunosuppressants FK506 and rapamycin have different effects on the biosynthesis of cytoplasmic actin during the early period of T cell activation.
221. Immunosuppressants for auto-immune diseases and pregnancy.
222. Immunosuppressants for genetic disorders--drug treatment of choice.
223. Immunosuppressants for therapy of patients with ulcerative colitis.
224. Immunosuppressants hit the target.
225. Immunosuppressants implicate protein phosphatase regulation of K+ channels in guard cells.
226. Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases.
227. Immunosuppressants in patients with AIDS.
228. Immunosuppressants in periarteritis nodosa.
229. Immunosuppressants in systemic necrotizing vasculitides.
230. Immunosuppressants in systemic vasculitides.
231. Immunosuppressants in the treatment of inflammatory bowel disease.
232. Immunosuppressants in the treatment of pemphigus.
233. Immunosuppressants in the treatment of polymyositis (author's transl).
234. Immunosuppressants in treatment of patients with AIDS.
235. Immunosuppressants inhibit hormone-stimulated Mg2+ uptake in mouse distal convoluted tubule cells.
236. Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms.
237. Immunosuppressants of tomorrow.
238. Immunosuppressants promote adult dorsal root regeneration into the spinal cord.
239. Immunosuppressants reduce venous thrombosis relapse in Behçet's disease.
240. Immunosuppressants suppressing signal 2 of T-cell activation enable CsA to induce operational transplantation tolerance in a strongly immunogenic heart allograft model in rats.
241. Immunosuppressants testing in transplantation.
242. Immunosuppressants used in a steroid-sparing strategy for childhood uveitis.
243. Immunosuppressants, immunophilins, and the nervous system.
244. Immunosuppressants, infection, and inflammation.
245. Immunosuppressants.
246. Immunosuppressants.
247. Immunosuppressants.
248. Immunosuppressants.
249. Immunosuppressants.
250. Immunosuppressants: cellular and molecular mechanisms of action.
251. Immunosuppressants: JC virus encephalopathy. Rare but fatal.
252. Immunosuppressants: neuroprotection and promoting neurological recovery following peripheral nerve and spinal cord lesions.
253. Immunosuppressants: tools to investigate the physiological role of cytokines.
254. Immunosuppressants: what's new?
255. Immunosuppressants-ligands as neuroprotectants.
256. Immunosuppressive activity of serum taken from a liver transplant recipient after withdrawal of immunosuppressants.
257. Impact of immunosuppressants on host tissues and tolerance.
258. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation.
259. Impact of stress, distress and feelings of indebtedness on adherence to immunosuppressants following kidney transplantation.
260. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.
261. Improved clinical outcomes in Chinese renal allograft recipients receiving lower dose immunosuppressants.
262. Improved influenza and pneumococcal vaccination in rheumatology patients taking immunosuppressants using an electronic health record best practice alert.
263. Improvement of the maintenance therapy after methylprednisolone pulse therapy--effect of prednisolone combined with immunosuppressants.
264. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.
265. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.
266. Incidence of side effects of immunosuppressants commonly used in heart transplantation.
267. Inclusion of MPA and in a rapid multi-drug LC-tandem mass spectrometric method for simultaneous determination of immunosuppressants.
268. Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses.
269. Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation.
270. Influence of classic immunosuppressants on spleen colony formation in mice. 3. Concentration of colony forming units in bone marrow and spleens of cyclophosphamide-treated mice.
271. Influence of classical immunosuppressants on spleen colony formation in mice. II. Stimulation of endogenous spleen colony formation by cyclophosphamide pretreatment prior to sublethal irradiation.
272. Influence of classical immunosuppressants on spleen colony formation in mice.
273. Influence of immunosuppressants against Dirofilaria immitis infection in dogs.
274. Influence of immunosuppressants on the establishment of Paragonimus miyazakii in albino rats.
275. Influence of pretreatment with immunosuppressants on O-demethylation of dextromethorphan in isolated perfused rat liver.
276. Inhibition of acute rejection of heart graft in rats without immunosuppressants after intrathymic myocardial cell inoculation in the neonatal period.
277. Inhibition of collagen II-induced arthritis in mice--a comparison of the effects of Sch 24937, immunosuppressants and nonsteroidal antiinflammatory drugs on the clinical expression of disease.
278. Inhibition of epithelial replacement by nonspecific immunosuppressants accelerates rat orthotopic tracheal allograft rejection.
279. Inhibition of MD-1 expression by immunosuppressants or antisense oligodeoxynucleotides on skin allograft survival in mice.
280. Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine.
281. Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
282. Interaction between conidia, lung macrophages, immunosuppressants, proinflammatory cytokines and transcriptional regulation.
283. Interactions between antiinfective agents and immunosuppressants.
284. Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.
285. Interleukin-2 receptor (CD25) upregulation on human T-lymphocytes: sensitivity to immunosuppressants is defined by the mode of T-lymphocyte activation.
286. Is the risk of lymphoma increased by immunosuppressive therapy in patients with inflammatory bowel disease? The missing link for considering early immunosuppressants.
287. Isolated rat hepatocytes (9)--the effects of immunosuppressants.
288. Isoxazolylthioamides as potential immunosuppressants a combinatorial chemistry approach.
289. Juxta-clavicular beaded lines in a kidney transplant patient receiving immunosuppressants.
290. Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation.
291. Kinetics and requirements for activation of macrophages for fungicidal activity: effect of protein synthesis inhibitors and immunosuppressants on activation and fungicidal mechanism.
292. Lassa and Mozambique viruses: cross protection in experiments on mice and action of immunosuppressants on experimental infections.
293. Latent Pneumocystis carinii infection in commercial rat colonies: comparison of inductive immunosuppressants plus histopathology, PCR, and serology as detection methods.
294. Letter: Paraquat poisoning treated with immunosuppressants and potassium aminobenzoate.
295. Liquid chromatography-tandem mass spectrometry work flow for parallel quantification of methotrexate and other immunosuppressants.
296. Long lasting side effects of immunosuppressants in children.
297. Longer transplanted heart allograft survival in rats without immunosuppressants after intrathymic myocardial cell inoculation in the neonatal period.
298. Long-term effects of immunosuppressants in steroid-dependent nephrotic syndrome.
299. Long-term use of a combination of immunosuppressants, and antiaggregant and an anticoagulant in the treatment of glomerulonephritis.
300. Long-term use of immunosuppressants in patients with kidney transplants.
301. Low-density lipoprotein adsorption therapy can restore drug sensitivity for immunosuppressants via inhibitory effects upon MDR-1 gene expression.
302. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom.
303. Macrolide immunosuppressants.
304. Macromolecular immunosuppressants.
305. Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer?
306. Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin.
307. Median effect analysis of efficacy versus adverse effects of immunosuppressants.
308. Mesenchymal stem cells as cellular immunosuppressants.
309. Metabolism and function of phagocytes after combined administration of immunosuppressants and biologically active substances.
310. Methyl inosine monophosphate (MIMP) augments T-lymphocyte mitogen responses and reverses various immunosuppressants.
311. Microbial deaminases as immunosuppressants.
312. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study.
313. Molecular action mechanisms of the therapeutic agents for kidney diseases: Immunosuppressants.
314. Molecular mechanisms of neuroprotective action of immunosuppressants--facts and hypotheses.
315. Molecular mechanisms of new immunosuppressants.
316. Monitoring and secondary effects of immunosuppressants in the transplant.
317. Monoclonal antibodies to CD3 as immunosuppressants.
318. Multicentric Castleman's disease treated with antivirals and immunosuppressants.
319. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab.
320. Multiple sclerosis: pilot therapeutic trial of immunosuppressants.
321. Mutagenicity of combined immunosuppressants.
322. Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation.
323. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults.
324. Myelopathy in Sjögren's syndrome: role of nonsteroidal immunosuppressants.
325. Nephrotoxicity of antibiotics and immunosuppressants. Proceedings of the satellite symposium. Sapporo, Japan, July 26-28, 1986.
326. Nephrotoxicity of immunosuppressants in rats: comparison of macrolides with cyclosporin.
327. Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models.
328. New immunosuppressants and HLA matching.
329. New immunosuppressants in BMT/GVHD.
330. New immunosuppressants in clinical trial.
331. New immunosuppressants with potential implication in multiple sclerosis.
332. New immunosuppressants: testing and development in animal models and the clinic: with special reference to DSG.
333. New natural immunosuppressants. A comparison by their mechanism of action with cyclosporin A.
334. New small molecule immunosuppressants for transplantation: review of essential concepts.
335. Non-specific immunosuppressants in the treatment of multiple sclerosis.
336. Nonsteroid immunosuppressants in endocrine orbitopathy.
337. Novel immunosuppressants in asthma.
338. Novel immunosuppressants.
339. Novel mycophenolic adenine bis(phosphonate)s as potential immunosuppressants.
340. On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants.
341. Orally administered immunosuppressants modify intestinal uptake of nutrients in rabbits.
342. Other immunosuppressants: azathioprine (Imurel), mycophenolate mofetil (Cellcept), cyclophosphamide (Endoxan).
343. Other novel immunosuppressants.
344. Overview of a 10-year experience on methods and compositions for inducing site-specific immunosuppression with topical immunosuppressants.
345. Patch-testing while on systemic immunosuppressants.
346. Pathogenicity of Mengo virus to mice. III. Potentiation of infection by immunosuppressants.
347. Pentalenolactone I and hygromycin A, immunosuppressants produced by Streptomyces filipinensis and Streptomyces hygroscopicus.
348. Peptidic immunosuppressants from the fungus Trichoderma polysporum.
349. Perianal cytomegalovirus ulcer following herpes simplex virus in a patient with idiopathic thrombocytopenic purpura treated with immunosuppressants.
350. Persistent dyspnea in a 59-year-old woman receiving immunosuppressants.
351. Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs.
352. Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients.
353. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises.
354. Pharmacokinetics and therapeutic drug monitoring of immunosuppressants.
355. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences.
356. Plant alkaloid tetrandrine and its analog block CD28-costimulated activities of human peripheral blood T cells: potential immunosuppressants in transplantation immunology.
357. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants.
358. Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants.
359. Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
360. Predicting behavior of immunosuppressants in liver transplantation.
361. Primary cutaneous nocardiosis in 2 patients on immunosuppressants.
362. Prodigiosins: a novel family of immunosuppressants with anti-cancer activity.
363. Production of inflammatory markers by HepG 2 cells stimulated with monocyte conditioned media: the effects of corticosteroid and other immunosuppressants.
364. Prostaglandin E2 stimulates amyloid precursor protein gene expression: inhibition by immunosuppressants.
365. Protection of pig liver against normothermic ischemia by immunosuppressants cyclosporine and azathioprine.
366. Protective effects of immunosuppressants and steroids against ischemia-reperfusion injury in cremaster muscle flap at microcirculatory level.
367. Provocative effects of the immunosuppressants rapamycin, tacrolimus, and dexamethasone on pneumonitis in contrast to the anti- pneumonitis effects of mycophenolate mofetil.
368. Psychopharmacologic issues in organ transplantation. Part I: Pharmacokinetics in organ failure and psychiatric aspects of immunosuppressants and anti-infectious agents.
369. Pyrazole bioisosteres of leflunomide as B-cell immunosuppressants for xenotransplantation and chronic rejection: scope and limitations.
370. Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants.
371. Radiotherapy plus cetuximab is safe in a head and neck cancer patient on immunosuppressants for liver transplant.
372. Rapid adhesion and spread of non-adherent colon cancer Colo201 cells induced by the protein kinase inhibitors, K252a and KT5720 and suppression of the adhesion by the immunosuppressants FK506 and cyclosporin A.
373. Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometry.
374. Recent advances in immunosuppressants.
375. Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants.
376. Reduction in murine Langerhans cell ATPase staining following topical but not systemic treatment with steroid and non-steroid immunosuppressants.
377. Refractory major aphthous stomatitis managed with systemic immunosuppressants: a case report.
378. Regeneration of ureter and pelvis from transversely cut and partially joined ureteral wall. Effect of immunosuppressants on the regeneration.
379. Regulation of alloreactivity in the popliteal lymph node assay by the new immunosuppressants: malononitrilamides.
380. Regulation of the immune response--what can be learnt from immunosuppressants?
381. Relapses in patients with microscopic polyangiitis with persistently positive antimyeloperoxidase for 4 years using maintenance immunosuppressants.
382. Remission induced by dose-reduction of immunosuppressants alone in a patient with post-transplant lymphoproliferative disorder of central nervous system origin.
383. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants.
384. Response to tetanus vaccination in infants exposed in utero to immunosuppressants for maternal autoimmune disorders.
385. Review article: Immunosuppressants in distal ulcerative colitis.
386. Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies.
387. Rheumatism patient must have surgery. Discontinuing immunosuppressants before operation?.
388. Risk of HBV reactivation under chemotherapy and immunosuppressants.
389. Search for new synthetic immunosuppressants II. Tetrazole analogues of hymenistatin I.
390. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
391. Sesquiterpenes as immunosuppressants.
392. Side effects of immunosuppressants used in rheumatology.
393. Signal transduction. Immunosuppressants at work.
394. Simple aromatics identified with a NFAT-lacZ transcription assay for the detection of immunosuppressants.
395. Simultaneous determination of four immunosuppressants by means of high speed and robust on-line solid phase extraction-high performance liquid chromatography-tandem mass spectrometry.
396. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography--tandem mass-spectrometry.
397. Sirolimus and FK778: a comparison of two anti-proliferative immunosuppressants for prevention of experimental obliterative airway disease.
398. Sirolimus/cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model.
399. SNF4435C and D, novel immunosuppressants produced by a strain of Streptomyces spectabilis. III. Immunosuppressive efficacy.
400. SNF4435C and D, novel immunosuppressants produced by a strain of Streptomyces spectabilis. II. Structure elucidation.
401. SNF4435C and D, novel immunosuppressants produced by a strain of Streptomyces spectabilis. I. Taxonomy, fermentation, isolation and biological activities.
402. Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants.
403. Steroids as immunosuppressants in pregnancy.
404. Stevastelins, a novel group of immunosuppressants, inhibit dual-specificity protein phosphatases.
405. Stevastelins, novel immunosuppressants produced by Penicillium.
406. Strategy of immunosuppressants usage for subjects with loss of renal function and infection control on RPGN.
407. Structures of calcineurin and its complexes with immunophilins-immunosuppressants.
408. Successful and cost-efficient replacement of immunoassays by tandem mass spectrometry for the quantification of immunosuppressants in the clinical laboratory.
409. Successful bone marrow plus cord blood stem cell transplantation in a girl who developed myelodysplastic syndrome from hepatitis-associated aplastic anemia treated with long-term immunosuppressants and growth factors.
410. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants.
411. Successful treatment of refractory septic arthritis caused by salmonella and staphylococcus aureus with preservation of graft function in a long-term renal transplant recipient by total withdrawal of immunosuppressants.
412. Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants.
413. Suppression of experimental autoimmune myasthenia gravis with new immunosuppressants: 15-deoxyspergualin and actinobolin.
414. Survival of patients with diffuse glomerulonephritis in disseminated lupus erythematosus treated with a combination of anticoagulants, corticosteroids and immunosuppressants.
415. Sustained suppression of xenoreactive natural antibodies: anti-IgM monoclonal antibody and anti-B cell immunosuppressants.
416. SW-163A and B, novel immunosuppressants produced by Streptomyces sp.
417. Systematic review of penetrating keratoplasty rejection treated by immunosuppressants.
418. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis.
419. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs.
420. Terprenins, novel immunosuppressants produced by Aspergillus candidus.
421. The "Medication Experience Scale for Immunosuppressants" (MESI): initial results for a new screening instrument in transplant medicine.
422. The continuous treatment of generalized myasthenia gravis with small doses of prednisolone with or wihtout immunosuppressants (author's transl).
423. The differences in liver regenerative rate after partial hepatectomy in rats treated wtih selected immunosuppressants.
424. The differential sensitivity of rat peripheral blood T cells to immunosuppressants: cyclophosphamide and dexamethasone.
425. The effect of different immunosuppressants on alloantigen dependent and independent factors involved in the development of chronic rejection in an animal model.
426. The effect of immunosuppressants and adoptive transfer in monocrotaline pyrrole pneumotoxicity.
427. The effect of immunosuppressants on experimental infection with Fasciola hepatica.
428. The effect of immunosuppressants on human leukocyte NADPH oxidase.
429. The effect of immunosuppressants on the development of Hymenolepis diminuta in mice.
430. The effects of different immunosuppressants on chronic allograft nephropathy by affecting the transforming growth factor-beta and Smads signal pathways.
431. The effects of immunosuppressants on FAS-mediated activation-induced cell death in human T lymphocytes.
432. The effects of immunosuppressants on vascular function, systemic oxidative stress and inflammation in rats.
433. The immunosuppressants cyclosporin A and FK506 equally ameliorate brain damage due to 30-min middle cerebral artery occlusion in hyperglycemic rats.
434. The influence of immunosuppressants on the fertility of males who undergo renal transplantation and on the immune function of their offspring.
435. The influence of the immunosuppressants OKT3 and ATG on immunological parameters.
436. The late effects of selected immunosuppressants on immunocompetence, disease incidence, and mean life-span. III. Disease incidence and life expectancy.
437. The late effects of selected immunosuppressants on immunocompetence, disease incidence, and mean life-span. I. Humoral immune activity.
438. The late effects of selected immunosuppressants on immunocompetence, disease incidence, and mean life-span. II. Cell-mediated immune activity.
439. The lungs and immunosuppressants: practical problems.
440. The macrolide immunosuppressants in dermatology: mechanisms of action.
441. The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents.
442. The syndrome of insulin resistance, acanthosis nigricans and an autoimmune disorder in diabetes mellitus treated with immunosuppressants.
443. The use of biologics and other immunosuppressants in the treatment of common inflammatory diseases in neuro-ophthalmology.
444. Therapeutic drug monitoring for immunosuppressants.
445. Therapeutic potential of macrolide immunosuppressants in dermatology.
446. Therapeutic strategies for optimal use of novel immunosuppressants.
447. Three-dimensional structure and actions of immunosuppressants and their immunophilins.
448. Tolerance induction in rat renal allografts by chemical modulation of accessory signals for lymphocyte activation without immunosuppressants.
449. Topical immunosuppressants, genital lichen sclerosus and the risk of squamous cell carcinoma: a case report.
450. Total synthesis of the immunosuppressants myriocin and 2-epi-myriocin.
451. Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality, and challenges.
452. Tracheal allograft transplantation in rats: the role of different immunosuppressants on preservation of respiratory epithelium.
453. Tracheal allotransplantation in beagle dogs without immunosuppressants.
454. Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease.
455. Treatment adherence in renal transplant recipients: a questionnaire survey on immunosuppressants.
456. Treatment of diffuse glomerulonephritis in adults with Schönlein-Henoch disease using a combination of anticoagulants, corticosteroids and immunosuppressants.
457. Treatment of myasthenia gravis with immunosuppressants (author's transl).
458. Treatment of neuro-immunologic diseases by immunosuppressants.
459. Treatment of periarteritis nodosa using immunosuppressants and glucocorticoids.
460. Treatment of periarteritis nodosa with immunosuppressants.
461. Treatment of periarteritis nodosa with immunosuppressants.
462. Treatment of severe forms of chronic active hepatitis with high doses of immunosuppressants.
463. Treatment of transplant rejection: are the traditional immunosuppressants good enough?
464. Treatment with cyclosporine of adult idiopathic nephrotic syndrome resistant to corticosteroids and other immunosuppressants.
465. Treatment with immunosuppressants FTY720 and tacrolimus promotes functional recovery after spinal cord injury in rats.
466. Tuberculosis, anti-TNF agents and other immunosuppressants: evolution of preventitive strategies.
467. Two cases of acute leukopenia induced by colchicine with concurrent immunosuppressants use in Behçet's disease.
468. Tyrosine kinase inhibitors and immunosuppressants perturb the myo-inositol but not the betaine cotransporter in isotonic and hypertonic MDCK cells.
469. Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin.
470. Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis.
471. Ushikulides A and B, immunosuppressants produced by a strain of Streptomyces sp.
472. Validation of an LC-MS/MS method to determine five immunosuppressants with deuterated internal standards including MPA.
473. Vascular manifestations of Behçet's syndrome associated with solitary ulcerations and resolved with immunosuppressants.
474. Viral infections in patients with inflammatory bowel disease on immunosuppressants.
475. When should immunosuppressants be prescribed to treat systemic vasculitides?
476. When worlds collide: immunosuppressants meet protein phosphatases.
477. Xanthines: ideal immunosuppressants for combination with cyclosporine?